Point72 Asset Management L.P. Has $9.21 Million Position in Progyny, Inc. (NASDAQ:PGNY)

Point72 Asset Management L.P. cut its holdings in Progyny, Inc. (NASDAQ:PGNY) by 32.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 534,074 shares of the company’s stock after selling 255,344 shares during the quarter. Point72 Asset Management L.P. owned about 0.63% of Progyny worth $9,213,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of PGNY. ProShare Advisors LLC boosted its holdings in shares of Progyny by 36.0% in the fourth quarter. ProShare Advisors LLC now owns 23,800 shares of the company’s stock valued at $411,000 after buying an additional 6,299 shares during the period. Nuveen Asset Management LLC lifted its position in Progyny by 38.4% in the 4th quarter. Nuveen Asset Management LLC now owns 295,979 shares of the company’s stock valued at $5,106,000 after acquiring an additional 82,087 shares in the last quarter. Numerai GP LLC boosted its stake in Progyny by 117.6% in the 4th quarter. Numerai GP LLC now owns 129,883 shares of the company’s stock worth $2,240,000 after purchasing an additional 70,191 shares during the period. Moore Capital Management LP acquired a new position in Progyny in the 4th quarter worth $1,382,000. Finally, Focus Partners Wealth increased its holdings in Progyny by 20.4% during the 4th quarter. Focus Partners Wealth now owns 60,189 shares of the company’s stock worth $1,038,000 after purchasing an additional 10,189 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PGNY. Canaccord Genuity Group cut their price target on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, May 12th. JPMorgan Chase & Co. boosted their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Bank of America upped their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Finally, BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Monday, March 31st. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.45.

Progyny Trading Up 1.6%

NASDAQ:PGNY opened at $22.30 on Monday. The stock has a market capitalization of $1.91 billion, a PE ratio of 38.45, a P/E/G ratio of 2.39 and a beta of 1.37. The firm has a fifty day simple moving average of $22.08 and a 200 day simple moving average of $19.79. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $30.42.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $324.04 million during the quarter, compared to analyst estimates of $307.86 million. During the same quarter last year, the business posted $0.17 earnings per share. The company’s revenue for the quarter was up 16.5% on a year-over-year basis. On average, equities analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.